logo
Think of Exercise as a Vaccine for Your Body

Think of Exercise as a Vaccine for Your Body

Medscape4 days ago
This transcript has been edited for clarity.
Let's talk today about how exercise can be viewed as a type of vaccine.
With a traditional vaccine, there is a controlled exposure to something harmful, which is typically a viral particle. That exposure, though, allows the immune system to be prepared to deal with that virus if it sees it again later on.
Exercise also has the appearance of harm on the surface. It doesn't always feel good in the moment. The whole body is working harder to meet the demands of the exercise. As a result of that extra stress during the exercise activity, the body is then better prepared to deal with stress that can occur from disease processes later on.
As a result of the aging process,organ systems are going to decline a little bit in function, and exercise is the best way to combat those declines. Let's think about something like pneumonia, where somebody might have a fever; they're going to be breathing heavy, and their heart's going to be working harder. For someone who's been exercising on a regular basis, their organ systems are better prepared to meet the higher demands associated with a disease process such as pneumonia.
In contrast, for someone who has not been exercising frequently, their organ systems have declined in function, and then as a result, they're more likely to be overwhelmed during the disease process. Someone might need medications to support their blood pressure during a pneumonia situation. Someone else might need a mechanical ventilator.
In this way, you could view exercise as training for the worst day of your life from a medical perspective. You want to make sure your organs are equipped to deal with stress when it's occurring in an uncontrolled environment, like from an infection such as pneumonia.
Vaccines may be a controversial topic for some, but I think exercise is one type of vaccine whose benefits we can all agree upon.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Jackson Parish Hospital teams up with TruBridge to support financial operations
Jackson Parish Hospital teams up with TruBridge to support financial operations

Yahoo

time12 minutes ago

  • Yahoo

Jackson Parish Hospital teams up with TruBridge to support financial operations

Jackson Parish Hospital, a critical access facility in Louisiana, US, has re-established its partnership with healthcare solutions company TruBridge to enhance its financial operations. With Under this strategic alliance, the 25-bed facility will implement TruBridge's technology driven, Complete Business Office (CBO) services. This move aims to improve the hospital's operational efficiency and financial health, encompassing revenue cycle management, billing, coding and claims management. The decision to return to TruBridge comes after a period of collaboration with another vendor since 2019. Jackson Parish CEO John Morgan said: 'The expertise at TruBridge is unlike any other that we experienced elsewhere. 'We see them as a leader in the community and critical access space and believe they understand our needs.' This renewed partnership builds upon a previous seven-year relationship. TruBridge is known for improving fiscal sustainability and securing efficient and accurate claims processing for health systems across the US. Its CBO services provide hospitals, ranging from critical access to 400-bed facilities, with solutions to stabilise operations, optimise cash flow, and achieve financial outcomes. TruBridge Financial Health general manager Merideth Wilson said: 'We are pleased to partner with Jackson Parish Hospital once again. Our shared mission to empower communities through fiscal sustainability is central to our relationship. 'Strong financial outcomes are integral to patient outcomes, and we're committed to helping communities thrive.' Earlier this year, TruBridge unveiled a partnership that integrated Microsoft Dragon Copilot with its electronic health record solution, aimed at boosting operational efficiency for hospitals and health systems throughout the US. Prior to this, Lady of the Sea General Hospital entered into a collaboration with TruBridge, focusing on enhancing patient care and the revenue cycle. "Jackson Parish Hospital teams up with TruBridge to support financial operations" was originally created and published by Hospital Management, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.

Palvella Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference
Palvella Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference

Yahoo

time12 minutes ago

  • Yahoo

Palvella Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference

WAYNE, Pa., Aug. 05, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no Food and Drug Administration (FDA)-approved therapies, today announced that Wes Kaupinen, Founder and Chief Executive Officer of Palvella, will participate in a fireside chat at the Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12, 2025, at 1:00 p.m. ET. A live webcast of the fireside chat will be available on the Events and Presentations section of Palvella's website at An archived replay of the webcast will be available for approximately 90 days following the presentation. About Palvella TherapeuticsFounded and led by rare disease drug development veterans, Palvella Therapeutics, Inc. (Nasdaq: PVLA) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. Palvella is developing a broad pipeline of product candidates based on its patented QTORIN™ platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Palvella's lead product candidate, QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin), is currently being evaluated in the Phase 3 SELVA clinical trial in microcystic lymphatic malformations and the Phase 2 TOIVA clinical trial in cutaneous venous malformations. For more information, please visit or follow Palvella on LinkedIn or X (formerly known as Twitter). QTORIN™ rapamycin is for investigational use only and has not been approved or cleared by the FDA or by any other regulatory agency for any Information InvestorsWesley H. KaupinenFounder and CEO, Palvella MediaMarcy NanusManaging Partner, Trilon Advisors, LLCmnanus@

Altimmune to Report Second Quarter 2025 Financial Results and Provide Business Update on August 12, 2025
Altimmune to Report Second Quarter 2025 Financial Results and Provide Business Update on August 12, 2025

Yahoo

time12 minutes ago

  • Yahoo

Altimmune to Report Second Quarter 2025 Financial Results and Provide Business Update on August 12, 2025

GAITHERSBURG, Md., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, today announced that it will report its second quarter 2025 financial results on Tuesday, August 12, 2025. Altimmune management will host a conference call at 8:30 am E.T. on August 12 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune's Investor Relations website at Participants who would like to join the call may register here to receive the dial-in numbers and unique PIN to access the call. Shortly after the call, a replay will be available on the Investor Relations website for up to three months. About Altimmune Altimmune is a late clinical-stage biopharmaceutical company focused on developing novel peptide-based therapeutics for liver and cardiometabolic diseases. The Company's lead program is pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH), Alcohol Use Disorder (AUD), Alcohol-Associated Liver Disease (ALD) and obesity. For more information, please visit Follow @Altimmune, Inc. on LinkedInFollow @AltimmuneInc on X Company Contact:Greg WeaverChief Financial OfficerPhone: 240-654-1450ir@ Investor Contact:Lee RothBurns McClellanPhone: 646-382-3403lroth@ Media Contact:Jake RobisonInizio Evoke, BiotechPhone: This press release was published by a CLEAR® Verified in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store